Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrimycin for Carbapenem-resistant Infections in HLH
NCT05988177Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2026
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Open-label, single-arm trial of carrimycin in bacterial infection, sponsored by Beijing Friendship Hospital. Primary endpoints: Cure rates of infections at 2 weeks and Overall response rate of HLH at 2 weeks. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
carrimycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05988177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05988177.